BioCentury | Apr 22, 2019
Company News

Lilly pays $35M up front to partner with Avidity on oligo conjugates

...Capital. Wilson is also president and CEO of cancer companies Kura Oncology Inc. (NASDAQ:KURA) and Wellspring Biosciences LLC...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...April 15. North is a veteran of multiple biotech companies including Kura Oncology Inc. (NASDAQ:KURA), Wellspring Biosciences LLC...
BioCentury | Mar 14, 2018
Translation in Brief

Raising KRAS

...For the first time, a joint research team from Wellspring Biosciences LLC and the Janssen Research & Development...
...inhibitor.” Cell (2018) Mary Romeo, Staff Writer Araxes Pharma LLC Johnson & Johnson Kura Oncology Inc. University of California San Francisco Wellspring Biosciences LLC K-Ras...
BioCentury | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

...actually bind the surface of KRAS and allosterically modulate the protein. In 2012, Shokat founded Wellspring Biosciences LLC...
...Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. University of California San Francisco, San Francisco, Calif. Wellspring Biosciences LLC...
BioCentury | Jan 9, 2014
Targets & Mechanisms

Covalent hits on KRAS

...mutations. The Ras pathway is our primary focus," said Troy Wilson, president and CEO of Wellspring Biosciences LLC...
...California, San Francisco , Calif. The University of Texas Southwestern Medical Center , Dallas, Texas Wellspring Biosciences LLC...
BioCentury | Mar 4, 2013
Company News

Araxes Pharma, J&J deal

...worldwide rights to commercialize any products. Araxes is the first publicly disclosed affiliate company of Wellspring Biosciences LLC...
BioCentury | Feb 28, 2013
Top Story

Araxes debuts with Janssen cancer deal

...worldwide rights to commercialize any products. Araxes is the first publicly disclosed affiliate company of Wellspring Biosciences LLC...
Items per page:
1 - 7 of 7
BioCentury | Apr 22, 2019
Company News

Lilly pays $35M up front to partner with Avidity on oligo conjugates

...Capital. Wilson is also president and CEO of cancer companies Kura Oncology Inc. (NASDAQ:KURA) and Wellspring Biosciences LLC...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...April 15. North is a veteran of multiple biotech companies including Kura Oncology Inc. (NASDAQ:KURA), Wellspring Biosciences LLC...
BioCentury | Mar 14, 2018
Translation in Brief

Raising KRAS

...For the first time, a joint research team from Wellspring Biosciences LLC and the Janssen Research & Development...
...inhibitor.” Cell (2018) Mary Romeo, Staff Writer Araxes Pharma LLC Johnson & Johnson Kura Oncology Inc. University of California San Francisco Wellspring Biosciences LLC K-Ras...
BioCentury | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

...actually bind the surface of KRAS and allosterically modulate the protein. In 2012, Shokat founded Wellspring Biosciences LLC...
...Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. University of California San Francisco, San Francisco, Calif. Wellspring Biosciences LLC...
BioCentury | Jan 9, 2014
Targets & Mechanisms

Covalent hits on KRAS

...mutations. The Ras pathway is our primary focus," said Troy Wilson, president and CEO of Wellspring Biosciences LLC...
...California, San Francisco , Calif. The University of Texas Southwestern Medical Center , Dallas, Texas Wellspring Biosciences LLC...
BioCentury | Mar 4, 2013
Company News

Araxes Pharma, J&J deal

...worldwide rights to commercialize any products. Araxes is the first publicly disclosed affiliate company of Wellspring Biosciences LLC...
BioCentury | Feb 28, 2013
Top Story

Araxes debuts with Janssen cancer deal

...worldwide rights to commercialize any products. Araxes is the first publicly disclosed affiliate company of Wellspring Biosciences LLC...
Items per page:
1 - 7 of 7